PMID: 9538686Apr 16, 1998Paper

A good antisense molecule is hard to find

Trends in Biochemical Sciences
A D Branch

Abstract

Antisense molecules and ribozymes capture the imagination with their promise of rational drug design and exquisite specificity. However, they are far more difficult to produce than was originally anticipated, and their ability to eliminate the function of a single gene has never been proven. Furthermore, a wide variety of unexpected non-antisense effects have come to light. Although some of these side effects will almost certainly have clinical value, they make it hard to produce drugs that act primarily through true antisense mechanisms and complicate the use of antisense compounds as research reagents. To minimize unwanted non-antisense effects, investigators are searching for antisense compounds and ribozymes whose target sites are particularly vulnerable to attack. This is a challenging quest.

References


❮ Previous
Next ❯

Citations

Jun 8, 2000·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·T Sijen, J M Kooter
Jan 8, 2005·Chembiochem : a European Journal of Chemical Biology·Michael Famulok, Günter Mayer
Mar 3, 2007·Digestive Diseases and Sciences·Gary L DavisGyongyi Szabo
May 30, 2002·Life Sciences·Beth M McMahonElliott Richelson
Jun 1, 2000·Advances in Enzyme Regulation·M A GijónC C Leslie
Jan 19, 2000·Trends in Pharmacological Sciences·K J Myers, N M Dean
Nov 5, 2002·Trends in Biotechnology·Michael Famulok, Sandeep Verma
Oct 2, 2002·Gene·N MacleanH Farahmand
Feb 27, 1999·Current Opinion in Biotechnology·M AfsharG Varani
Sep 16, 1998·Current Opinion in Chemical Biology·S Agrawal, Q Zhao
Jun 23, 1999·The Biochemical Journal·V DoyleM Crompton
Dec 12, 2001·HIV Medicine·N Dorman, A M Lever
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·H ShiJ T Lis
Jul 15, 2006·Nucleosides, Nucleotides & Nucleic Acids·Yoshihito UenoYukio Kitade
May 23, 2002·Antisense & Nucleic Acid Drug Development·Laura PapucciSergio Capaccioli
Mar 25, 2005·Oligonucleotides·Long ShenJui H Wang
Jul 15, 2003·Molecular Biology of the Cell·Patric TurowskiNed J C Lamb
Nov 25, 1998·Nucleic Acids Research·N K VaishF Eckstein
Oct 5, 2002·Nucleic Acids Research·Michael C GiddingsOlga V Matveeva
Oct 23, 2008·Journal of Bioinformatics and Computational Biology·Tamara B Sipes, Susan M Freier
Aug 10, 2010·Journal of Experimental & Clinical Cancer Research : CR·Jing XuYongquan Tian
May 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Dimitri SemizarovStephen W Fesik
Jun 9, 1999·Proceedings of the National Academy of Sciences of the United States of America·B M TylerE Richelson
Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·C R GeyerR Brent
May 11, 2000·Proceedings of the National Academy of Sciences of the United States of America·C WahlestedtJ Wengel
Jul 26, 2011·Journal of Ophthalmology·Jack M SullivanHeba E Abdelmaksoud
Jan 22, 2002·FEBS Letters·Alain AnselmetJean Massoulié

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.